Abstract:e20518 Background: Malignant pleural effusion (MPE) is an abnormal amount of fluid to collect between the chest wall and the lung, and it denotes an advanced malignant disease process. MPE presents a severe medical condition which can result in breathlessness, pain, cachexia and reduced physical activity. MPE is considered to bear cancer signatures because it contains tumor cells released from malignancies, thus can be applied in high-throughput sequencing for cancer screening. Cell-free DNA (cfDNA) in blood consists of small fragments released from apoptotic cells or cancer cells, and pathological conditions can influence this process. Therefore, detection of cfDNA in peripheral blood can identify abnormalities of individuals in a noninvasive manner. Here, we wonder the difference of MPE and cfDNA in lung cancer-related mutation detection. Methods: In this study, MPE and blood samples from 216 patients with late-stage lung cancer were collected and applied to library construction and next-generation sequencing. All samples were collected during August 2018 to December 2022. We focused on the key mutations in cancer-causing genes and drug treatment-related genes (e.g., EGFR, KRAS, BRAF, ERBB2, etc.). Statistical analysis was conducted to compare the detection results between MPE and cfDNA samples by Fisher’s exact test. Results: Among the 216 patients, 60 patients (60/216 = 27.8%) were identified as negative detection with no mutation detected in cancer-causing genes in MPE and blood samples. Of the remaining 156 pairs of samples, there were 118 (118/216 = 54.6%) pairs showing the positive detection in both MPE and blood samples. 12 patients (12/216 = 5.6%) demonstrated the positive detection in blood samples while negative detection in MPE samples. The other 26 patients (26/216 = 12%) demonstrated the positive detection in MPE but negative detection in blood samples. There is no significant difference in detection rates between two types of samples (p = 0.194). Similarity, we next focused on the mutations in drug treatment-related genes and identified 91 patients (91/216 = 42.1%) as negative detection. There were 85 patients (85/216 = 39.4%) showing the same positive detection both in MPE and blood samples. 13 patients (13/216 = 6%) demonstrated the positive detection in blood samples but negative detection in MPE samples. The other 27 patients (27/216 = 12.5%) demonstrated the positive detection in MPE but negative detection in blood samples. No significant difference in detection rates was observed between two types of samples (p = 0.211). Conclusions: The mutation detection results in MPE and blood samples turned out to be consistent in most conditions, suggesting an alternative application of MPE or blood samples in cancer screening. Nonetheless, it is still valuable to integrate the information in both MPE and blood samples for a higher detection sensitivity.

Value of Malignant Pleural Effusion Supernatants (mpes) in Epidermal Growth Factor Receptor (EGFR) Mutation Detection of Patients with Advanced Lung Adenocarcinoma (ADC).

Comparative Study of EGFR Mutations Detected in Malignant Pleural Effusion, Plasma and Tumor Tissue in Patients with Adenocarcinoma of the Lung

Malignant Pleural Effusion Supernatants Are Substitutes for Metastatic Pleural Tumor Tissues in EGFR Mutation Test in Patients with Advanced Lung Adenocarcinoma.

EGFR mutations in malignant pleural effusions from lung cancer

Liquid Biopsies Using Pleural Effusion-Derived Exosomal DNA in Advanced Lung Adenocarcinoma.

A Multicenter Real-World Study of Tumor-Derived DNA from Pleural Effusion Supernatant in Genomic Profiling of Advanced Lung Cancer.

Comparison of Epidermal Growth Factor Receptor Gene Mutations Identified Using Pleural Effusion and Primary Tumor Tissue Samples in Non-Small Cell Lung Cancer.

Malignant Pleural Effusion Cell Blocks Are Substitutes for Tissue in EML4‐ALK Rearrangement Detection in Patients with Advanced Non‐small‐cell Lung Cancer

Carcinoembryonic Antigen in Pleural Effusion of Patients with Lung Adenocarcinoma: a Predictive Marker for EGFR Mutation

Detection of EGFR Gene Mutation Status from Pleural Effusions and Other Body Fluid Specimens in Patients with Lung Adenocarcinoma

Epidermal Growth Factor Receptor Mutations In Plasma Dna Samples Predict Tumor Response In Chinese Patients With Stages Iiib To Iv Non-Small-Cell Lung Cancer

Analytic And Clinical Validation Of An Ultrasensitive, Quantitative Polymerase Chain Reaction Assay For Egfr Mutation Analysis With Circulating Tumor Dna

Impact of Plasma EGFR Mutation Fractions on Response to First Generation Tyrosine-Kinase Inhibitor in Treatment of Naïve Non-Small Cell Lung Cancer Patients

Malignant pleural effusion supernatant is an alternative liquid biopsy specimen for comprehensive mutational profiling

Clinical impact of pleural fluid carcinoembryonic antigen on therapeutic strategy and efficacy in lung adenocarcinoma patients with malignant pleural effusion

Analysis of Egfr Mutation Status in Tissue and Plasma for Predicting Response to Egfr-Tkis in Advanced Non-Small-Cell Lung Cancer

Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients.

EML4-ALK Rearrangement Detection in Malignant Pleural Effusions from Patients with Advanced Non-Small Cell Lung Cancer: Feasibility and Predictive Value.

Sputum cell-free DNA: Valued surrogate sample for the detection of <i>EGFR</i> exon 20 p.T790M mutation in patients with advanced lung adenocarcinoma and acquired resistance to EGFR-TKIs

Comparative analysis of the mutation detection using malignant pleural effusion and blood cell-free DNA samples in lung cancer.

Gene Alterations in Paired Supernatants and Precipitates from Malignant Pleural Effusions of Non-Squamous Non-Small Cell Lung Cancer